C

Cencora

Distributes medicines and supports patient care

Accountant 3

Full-TimeUpdated on 10/24/2026
No salary listed
Senior
Bachelor's
Bogotá, Bogota, Colombia
In PersonBased in Bogotá; work hours must overlap with US Eastern Time.
AccountingFinancial Accounting

About the job

Requirements
  • A bachelor's degree in Accounting, Finance, or a related field is required.
  • A minimum of 6 years of directly related accounting experience is required; 7–8 years is preferred.
  • At least 4 years of experience in accounting, financial reporting, close, or controllership activities is required.
  • Strong working knowledge of US GAAP is preferred.
  • Proven experience managing or coordinating with accounts payable shared services or centralized finance teams is required.
  • Fluent English proficiency in reading, writing, and communication is required.
  • Advanced proficiency in Microsoft Excel, including XLOOKUP, pivot tables, and complex formulas, is required.
  • Experience with SAP or a comparable enterprise resource planning system is required.
  • Advanced knowledge of Microsoft Excel, Word, PowerPoint, and Outlook is required.
  • The ability to work quickly and accurately under time and volume constraints, particularly during close periods, is required.
  • Strong analytical and problem-solving capabilities, including researching and resolving complex issues with limited direction, are required.
  • The ability to review and provide constructive feedback on peers' work is required.
  • The ability to collaborate effectively in a remote, cross-border team environment is required.
  • The ability to work independently and meet deadlines is required.
Responsibilities
  • Serve as the primary point of contact between the regional finance team and centralized accounts payable shared services; manage, track, and resolve escalations, vendor disputes, invoice discrepancies, and payment inquiries.
  • Act as the regional point person for SAP Ariba, supporting users with purchase order issues, invoice submission, requisition workflows, and escalations to the Ariba support team.
  • Ensure accounts payable and Ariba processes function accurately and comply with company policies; document recurring issues and recommend process improvements.
  • Contribute to and help drive the monthly, quarterly, and annual US financial close, including preparing and posting journal entries, accruals, and adjusting entries, and directly executing tasks as needed to meet close deadlines.
  • Prepare and review financial reporting packages and variance analyses for the North America region.
  • Lead preparation of audit schedules and manage responses to internal and external auditor requests for the region.
  • Own World Customs Brokerage accounting end-to-end by developing a thorough understanding of billing processes, workflows, and systems; ensure transactions are accurately journalized in SAP under US GAAP; reconcile balance sheet accounts monthly; and serve as the team's subject matter resource for World Customs Brokerage accounting questions.
  • Own World Courier Canada accounting end-to-end in collaboration with the local general ledger and reporting accountant, ensuring accurate and complete Canadian financials, balance sheet reconciliations, journal entries, and period-end close; serve as the primary liaison between Canada finance and the Regional Controller for issue escalation and close-status updates.
  • Own and manage intercompany accounting across North America entities, including transaction recording, reconciliations, out-of-balance resolution, and coordination of intercompany eliminations during monthly close.
  • Serve as the subject matter resource for accounts receivable and intercompany accounting policy questions from the broader team.
  • Lead preparation and review of high-complexity general ledger reconciliations, including those involving significant judgment, aged items, or cross-entity implications; research and resolve unusual reconciling items using US GAAP and company policy.
  • Research accounting standards independently, including Accounting Standards Codification guidance, Financial Accounting Standards Board updates, and corporate policy changes; present findings and recommended accounting treatment to the Regional Controller and assist with technical accounting memos as needed.
  • Lead documentation of key accounting processes, procedures, and internal controls to support consistency, knowledge retention, and audit readiness; review and improve existing workpapers to reflect current processes.
  • Create and maintain standardized journal-entry templates for recurring entries to reduce manual effort and improve accuracy; identify other opportunities where templates or documented procedures can improve efficiency.
  • Own the technical review of journal entries, reconciliations, and financial reports prepared by the Accountant II, ensuring accuracy and compliance with US GAAP; provide real-time coaching and serve as the first escalation point before issues are elevated to the Regional Controller.
  • Maintain working knowledge of Accountant II responsibilities—including journal entries, balance sheet and bank reconciliations, lease accounting under ASC 842, accounts payable and accounts receivable support, and close-checklist management—and perform these tasks during absences, peak volume, or transitions.
  • Identify opportunities to cross-train and document Accountant II processes to reduce key-person risk and build organizational resilience.
  • Act as a trusted advisor and primary escalation resource for the Regional Controller on emerging accounting issues, policy questions, operational coverage needs, and ad hoc projects.
  • Communicate and collaborate daily with US-based employees via email, Microsoft Teams, and video calls, all conducted in English.
  • Identify opportunities to strengthen internal controls and improve accounting processes; ensure compliance with SOX requirements, US GAAP, and company policies.
  • Maintain organized and accurate financial records and supporting documentation; complete required training and stay current with changes to accounting standards.
Desired Qualifications
  • Seven to eight years of directly related accounting experience is preferred.
  • Experience supporting US-based or multinational operations is strongly preferred.
  • Strong working knowledge of US GAAP is preferred.

About the company

Cencora buys and distributes medicines for pharmacies, hospitals and physician practices, while helping drug manufacturers bring treatments to patients. Its businesses combine wholesale supply networks with specialty distribution for complex therapies and services that support prescribing and patient access. Customers order medicines through its distribution systems, and its teams manage sourcing, storage and delivery alongside pharmacy operations and manufacturer support. It earns revenue from pharmaceutical sales and fees for logistics and healthcare services. The parent company was formed in 2001 through the merger that created AmerisourceBergen, adopted the Cencora name in 2023, and is headquartered in Conshohocken, Pennsylvania.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

2001

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy contracts deepen customer ties: Cencora negotiates insurer agreements and handles administrative work through its managed-care networks.
  • Eligible US staff gain retirement support: Cencora counts student-loan payments toward its employer match, up to 4% of pay.
  • Drug demand expands sales: Cencora reported 5.1% quarterly revenue growth in August 2026, led by higher US volumes.

What critics are saying

  • Customer dependence concentrates risk: Walgreens and Boots supplied 25% of Cencora's fiscal 2025 revenue, reported in November 2025.
  • Legal liabilities tie up cash: Cencora's November 2025 filing recorded $4.3 billion in opioid settlements, payable over 13 years.
  • Warehouse work is physical: Cencora's day-shift associate listing requires repeated lifting up to 50 pounds and overtime availability.

What makes Cencora unique

  • Independent pharmacies get a shared brand: Cencora's Good Neighbor Pharmacy franchise supports their merchandising and store identity.
  • Specialty shipments use reusable packaging: Cencora's World Courier Cocoon containers combine passive temperature control with live location monitoring.
  • Medicines arrive ready for bedside checks: Cencora's American Health Packaging sells barcoded unit doses that support hospital scanning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Parental Leave
  • Adoption Assistance
  • Infertility Coverage
  • Family Planning Benefits
  • Behavioral Health Solutions
  • Professional Development Budget
  • Training Programs

Company News

Financial News
Oct 21st, 2026
Cencora to buy American Oncology Network in $2.4bn deal

Cencora agrees to buy American Oncology Network for $2.4bn enterprise value, but a stockholder rollover means it may land only 75% of the company.

Yahoo Finance
Oct 16th, 2026
Cencora stock: $332.8B revenue, 14.4% EPS growth and 50.2% ROIC

Cencora, the pharmaceutical distributor formerly known as AmerisourceBergen, has risen 6% to $341.69 per share over the past six months. The S&P 500 gained 9.7% in the same period. The New York Stock Exchange-listed company (NYSE:COR) connects drug manufacturers with healthcare providers and offers logistics, data analytics, and consulting services. It rebranded in 2023. Its revenue reached $332.8 billion over the past 12 months, giving it scale and bargaining power with suppliers. That matters in a low-margin, volume-driven business. Earnings per share grew at a 14.4% compound annual rate over five years, outpacing 10.2% annualised revenue growth. Its five-year average return on invested capital was 50.2%. The shares trade at 17.4 times forward earnings.

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.